Search - tctmd.com

Displaying 101 - 120 of 162

Sort: Relevancy | Date

News Daily News

Aspirin as Standalone Stroke Protection Still Overused for Patients With A-fib

Todd Neale

June 27, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

Todd Neale

April 06, 2016

News Daily News

美国心脏病专家为房颤患者使用口服抗凝药物的比例不足

Todd Neale

March 21, 2016

News Daily News

US Cardiologists Are Underusing Oral Anticoagulation for A-fib

Todd Neale

March 21, 2016

News Daily News

Los Cardiólogos de EE.UU. Infrautilizan la Anticoagulación Oral en el Manejo de la FA

Todd Neale

March 21, 2016

News Daily News

抗凝诊所在非华法林方案的时代的崭新作用

Todd Neale

March 01, 2016

News Daily News

Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina

Todd Neale

March 01, 2016

News Daily News

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

Todd Neale

March 01, 2016

News Conference News ISC 2016

To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds

Michael O'Riordan

February 23, 2016

News Daily News

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

Todd Neale

January 25, 2016

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Conference News AHA 2015

Is Watchman Cost-effective? That Depends Where You Look

Todd Neale

November 07, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

Todd Neale

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

Todd Neale

October 26, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

Advertisement

Aspirin as Standalone Stroke Protection Still Overused for Patients With A-fib

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

美国心脏病专家为房颤患者使用口服抗凝药物的比例不足

US Cardiologists Are Underusing Oral Anticoagulation for A-fib

Los Cardiólogos de EE.UU. Infrautilizan la Anticoagulación Oral en el Manejo de la FA

抗凝诊所在非华法林方案的时代的崭新作用

Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Is Watchman Cost-effective? That Depends Where You Look

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content